International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data.

Arber DA, et al. Blood. 2022;140(11):1200-1228.

Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis.

Coltro G, et al. Blood Cancer J. 2022;12(8):116.

Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis.

Gerds AT, et al. Blood Adv. 2020;4(22):5825-5835.

Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis.

Gerds AT, et al. Blood. 2024;8(17):4511-4522.

Momelotinib vs ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial.

Gupta V, et al. Leuk Lymphoma. 2024;65(7):965-977.

The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms.

Khoury JD, et al. Leukemia. 2022;36(7):1703-1719.

Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial.

Mascarenhas J, et al. JAMA Oncol. 2018;4(5):652-659.

Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis.

Mesa R, et al. Leukemia. 2022;36(9):2261-2268.

Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial.

Mesa RA, et al. Lancet Haematol. 2017;4(5):e225-e236.

Ruxolitinib in cytopenic myelofibrosis: response, toxicity, drug discontinuation, and outcome.

Palandri F, et al. Cancer. 2023;129(11):1704-1713.